1. The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, May 2023 Subject(s): BuprenorphineBuprenorphine, Naloxone Drug CombinationGovernment RegulationMedicare Part DOpioid-Related Disorders -- drug therapyUnited States
